Coagulation Factor Deficiency Epidemiology Forecast 2025-2034

Coagulation factor deficiencies, such as hemophilia, are hereditary disorders that cause abnormal bleeding. Hemophilia A affects 1 in 5000 males, with over 400,000 males affected globally. In the United States, 33,000 males live with hemophilia. Treatment involves clotting factor replacement and other supportive therapies to manage bleeding episodes.

Coagulation Factor Deficiency Epidemiology Forecast Report Coverage

The “Coagulation Factor Deficiency Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of coagulation factor deficiency. It projects the future incidence and prevalence rates of coagulation factor deficiency across various populations. The study covers age and type as major determinants of the coagulation factor deficiency-affected population. The report highlights patterns in the prevalence of coagulation factor deficiency over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on the epidemiology of coagulation factor deficiency in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Coagulation Factor Deficiency: Disease Overview

Coagulation factor deficiencies, including hemophilia, are conditions where the blood’s ability to clot is impaired due to a lack or deficiency of specific clotting factors. Hemophilia, the most common of these disorders, is X-linked and primarily affects males. Hemophilia A is caused by a deficiency in factor VIII, while Hemophilia B results from a lack of factor IX. Symptoms include prolonged bleeding, easy bruising, and spontaneous internal bleeding. Diagnosis is based on clotting tests, and treatment often involves replacement therapies with clotting factors. Prevention of bleeding episodes and managing complications are key to improving quality of life.

Coagulation Factor Deficiency: Treatment Overview

Treatment for coagulation factor deficiencies, such as hemophilia, primarily involves replacing the missing clotting factors. Factor replacement therapy is the cornerstone, with recombinant clotting factors or plasma-derived concentrates administered intravenously. For mild cases, infusions may be given on-demand during bleeding episodes, while severe cases may require regular prophylactic treatments to prevent spontaneous bleeding. In addition to factor replacement, desmopressin may be used for Hemophilia A to stimulate the release of stored clotting factors. Antifibrinolytics, such as tranexamic acid, help prevent bleeding. Patients may also undergo physical therapy to manage joint health and improve mobility, alongside genetic counselling for family planning.

Epidemiology

The coagulation factor deficiency epidemiology section offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. The publisher provides both current and predicted trends for coagulation factor deficiency by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for coagulation factor deficiency and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• The most common X-linked hereditary disorder of hemostasis, Hemophilia A affects 1 in 5000 males and accounts for 80% of all hemophilia cases.
• It is estimated that over 400,000 males worldwide are affected, with many remaining undiagnosed in developing regions.
• The prevalence of Hemophilia B is 3.8 per 100,000 live males and 5 per 100,000 males at birth. The incidence rate is consistent across all ethnic groups.
• Although vitamin K deficiency is found in 8% to 31% of typically healthy adults, it rarely causes clinically significant bleeding.

Country-wise Coagulation Factor Deficiency Epidemiology

The coagulation factor deficiency epidemiology data and findings for the United States, EU-4 (Germany, Spain, Italy, France), the United Kingdom, Japan, and India are also provided in the epidemiology section.

In the United States, approximately 33,000 males are living with hemophilia, with a prevalence of 1 in 125,000 males globally. Hemophilia A is the most common, affecting 1 in 5000 males, while Hemophilia B has a prevalence of 3.8 per 100,000 live males. In infants, Vitamin K Deficiency Bleeding (VKDB) is more common before they start regular foods, with late VKDB occurring in 1 in 14,000 to 1 in 25,000 infants. Babies not receiving a vitamin K shot at birth are 81 times more likely to develop late VKDB.

Scope of the Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of coagulation factor deficiency based on several factors.
• Coagulation Factor Deficiency Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The report helps to identify the patient population and the unmet needs of coagulation factor deficiency are highlighted along with an assessment of the disease's risk and burden.

Key Questions Answered

• What are the key findings of coagulation factor deficiency epidemiology in the 8 major markets?
• What will be the total number of patients with coagulation factor deficiency across the 8 major markets during the forecast period?
• What was the country-wise prevalence of coagulation factor deficiency in the 8 major markets in the historical period?
• Which country will have the highest number of coagulation factor deficiency patients during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of coagulation factor deficiency during the forecast period of 2025-2034?
• What are the currently available treatments for coagulation factor deficiency?
• What are the disease risks, signs, symptoms, and unmet needs of coagulation factor deficiency?

This product will be delivered within 3-5 business days.